NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Fluvastatin in the Therapy of Acute Coronary Syndrome

Phase 4

Completed

Conditions: Coronary Disease
Myocardial Infarction

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-16

Lead Sponsor: Novartis

Target Recruit Count: 1000

Registration Number: NCT00171275

Locations: 🇨🇿
Novartis, Praha, Czech Republic

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

Phase 3

Terminated

Conditions: Hypertension

Interventions: Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1
Drug: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2
Drug: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Drug: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter

First Posted Date: 2005-09-15

Last Posted Date: 2023-10-24

Lead Sponsor: Novartis

Target Recruit Count: 11506

Registration Number: NCT00170950

Locations: 🇩🇰
sites in Denmark, Denmark, Denmark
🇫🇮
sites in Finland, Finland, Finland
🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

and more 2 locations

Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid

Phase 4

Completed

Conditions: Breast Cancer With Metastatic Bone Disease

Interventions: Drug: Zoledronic acid

First Posted Date: 2005-09-15

Last Posted Date: 2023-08-18

Lead Sponsor: Novartis

Target Recruit Count: 116

Registration Number: NCT00172029

Locations: 🇹🇷
Novartis Investigative Site, Trabzon, Turkey

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

Phase 4

Completed

Conditions: Diastolic Dysfunction, Symptomatic Heart Failure

First Posted Date: 2005-09-15

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 150

Registration Number: NCT00171106

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-19

Lead Sponsor: Novartis

Target Recruit Count: 40

Registration Number: NCT00166725

Locations: 🇮🇹
Orbassano, Orbassano, Italy

The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2005-09-12

Last Posted Date: 2023-12-14

Lead Sponsor: Novartis

Target Recruit Count: 55

Registration Number: NCT00154323

Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Phase 4

Completed

Conditions: Renal Transplantation

Interventions: Drug: Cyclosporine
Drug: Everolimus
Drug: Enteric-coated mycophenolate sodium
Drug: Corticosteroids

First Posted Date: 2005-09-12

Last Posted Date: 2013-11-13

Lead Sponsor: Novartis

Target Recruit Count: 300

Registration Number: NCT00154310

Locations: 🇨🇭
Novartis Pharma AG, Basel, Switzerland
🇨🇭
Novartis Investigational Sites, Bern, Switzerland

Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients

Phase 3

Completed

Conditions: Organ Transplantation, Renal Transplantation

Interventions: Drug: Everolimus (Certican)
Drug: Cyclosporine (Neoral)
Drug: Steroid
Drug: Basiliximab (Simulect)

First Posted Date: 2005-09-12

Last Posted Date: 2018-08-09

Lead Sponsor: Novartis

Target Recruit Count: 114

Registration Number: NCT00154284

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis, Hip

First Posted Date: 2005-09-12

Last Posted Date: 2012-05-21

Lead Sponsor: Novartis

Target Recruit Count: 1200

Registration Number: NCT00154219

Locations: 🇬🇧
Various Sites, Multiple Cities, United Kingdom
🇺🇸
For US Site Information, contact Novartis Pharmaceuticals, East Hanover, New Jersey, United States

A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.

Phase 4

Completed

Conditions: Kidney Transplantation

First Posted Date: 2005-09-12

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis

Target Recruit Count: 20

Registration Number: NCT00154245

Home Terms & Conditions Privacy Policy